التفاصيل البيبلوغرافية
| العنوان: |
To the editor: Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. |
| المؤلفون: |
Lendvai, Nikoletta1,2, Yee, Andrew J.3, Tsakos, Ioanna1, Alexander, Aeri1, Devlin, Sean M.4, Hassoun, Hani1,2, Korde, Neha1,2, Lesokhin, Alexander M.1,2, Landau, Heather2,5, Mailankody, Sham1,2, Koehne, Guenther2,5, Chung, David J.2,5, Landgren, Ola1,2, Raje, Noopur S.3, Giralt, Sergio2,5 giralts@mskcc.org |
| المصدر: |
Blood. 5/12/2016, Vol. 127 Issue 19, p2355-2356. 2p. |
| مصطلحات موضوعية: |
*PROTEIN-tyrosine kinases, *MULTIPLE myeloma |
| People: |
YAKES, F. M. |
| مستخلص: |
A letter to the editor is presented in response to the article "Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth" by F. M. Yakes, and colleagues in the 2011 issue. |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder